Every 8-K that Akero Therapeutics, Inc. (AKRO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AKRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKRO filings page.
Akero Therapeutics agreed to be acquired by Novo Nordisk through a merger that will make Akero a wholly owned subsidiary of Novo Nordisk. The transaction includes cash consideration and a contingent value right (CVR) structure that awards one CVR per share and ties payments to specified regulatory and commercial milestones; in-the-money stock options will be cashed out plus converted into CVRs on a per-share basis. The merger is subject to customary closing conditions including antitrust and foreign investment clearances and approval by holders of a majority of Akero's common stock. Akero will file a proxy statement with additional details and warns that CVRs may yield no payment if milestones are not met and that regulatory approvals, competing offers, or other closing conditions could prevent or delay completion.
Akero Therapeutics, Inc. voluntarily repaid in full its outstanding debt under a term loan facility with Hercules Capital. On September 23, 2025, the company paid an aggregate $37.6 million, covering all outstanding principal, accrued and unpaid interest, fees, costs and expenses under its Loan and Security Agreement.
Following receipt of this payoff amount, all obligations, covenants, debts and liabilities under the loan were satisfied and discharged, and the Loan Agreement and related documents were terminated, other than the existing warrants. The facility had allowed borrowings of up to $150 million, of which Akero had drawn $35 million at a variable interest rate with a scheduled maturity in March 2027.
Akero Therapeutics, Inc. filed a current report disclosing that it has announced its financial results for the quarter ended June 30, 2025. The company released these quarterly results through a press release dated August 8, 2025, which is included as Exhibit 99.1. This press release is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other SEC filings unless specifically referenced.